CAR-expressing NK-92 cells as cell therapeutic agents

US10550197B2 · kind B2 · utility

Assignees

• CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS · DE
• DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH · DE

Inventors

• Winfried Wels · Emmendingen, DE
• Kurt Schonfeld · Langen, DE
• Torsten Tonn · Dresden, DE
• Manuel Grez · Heidelberg, DE
• Congcong Zhang · Frankfurt, DE

Key dates

• Filing date: Jun 18, 2015
• Grant date: Feb 4, 2020
• Expiry date: Dec 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.